Other Species / Isoforms
  MRLC2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2
______MSSKKAKTK
1 0
MRLC2 (human) ______MSSKKAKTK S2
MRLC2 (mouse) ______MssKKAKTK S2-p
MRLC2 (rat) ______MSSKKAKTK S2
MRLC2 (cow) ______MSSKRAKTK S2
S3
_____MSSKKAKTKt
1 0
MRLC2 (human) _____MSSKKAKTKt S3
MRLC2 (mouse) _____MssKKAKTKT S3-p
MRLC2 (rat) _____MSSKKAKTKT S3
MRLC2 (cow) _____MSSKRAKTKT S3
T10-p
SKKAKTKttKKRPQR
0 4
MRLC2 (human) SKKAKTKttKKRPQR T10-p
MRLC2 (mouse) sKKAKTKTTKKRPQR T10
MRLC2 (rat) SKKAKTKTTKKRPQR T10
MRLC2 (cow) SKRAKTKTTKKRPQR T10
T11-p
KKAKTKttKKRPQRA
0 6
MRLC2 (human) KKAKTKttKKRPQRA T11-p
MRLC2 (mouse) KKAKTKTTKKRPQRA T11
MRLC2 (rat) KKAKTKTTKKRPQRA T11
MRLC2 (cow) KRAKTKTTKKRPQRA T11
T19-p
KKRPQRAtsNVFAMF
Upstream
Downstream
34 329
Effects on Biological Processes:
  • cell motility, altered
  • cytoskeletal reorganization
Kinase, in vitro:
  • DAPK3 (human)
  • DLK (human)
  • ILK (human)
  • ROCK1 (human)
  • smMLCK (human)
Putative in vivo kinases:
  • DAPK3 (human)
  • ROCK1 (human)
Regulatory protein:
  • ACTG1 (human)
  • AFAP1L1 (human)
  • ARHGAP22 (human)
  • Cas-L (human)
  • DOCK3 (human)
  • HRas (mouse)
  • ITGB3 (human)
  • PLK3 (human)
  • RAC1 (human)
  • ROCK1 (human)
  • Src (human)
  • WAVE2 (human)
Treatment
  • anti-EPCR
  • APC
  • BX795
  • calyculin_A
  • cell_detachment
  • EDTA
  • EGF
  • ephrin_A1
  • exoenzyme_C3
  • fibronectin
  • GF109203X
  • integrilin
  • metastatic potential
  • miRNA
  • nocodazole
  • okadaic_acid
  • phorbol_ester
  • PP2
  • PP3
  • serum
  • serum_starvation
  • siRNA
  • Su11274
  • thrombin
  • vanadate
  • Y27632
MRLC2 (human) KKRPQRAtsNVFAMF T19-p
MRLC2 (mouse) KKRPQRAtsNVFAMF T19-p
MRLC2 (rat) KKRPQRAtsNVFAMF T19-p
MRLC2 (cow) KKRPQRAtsNVFAMF T19-p
S20-p
KRPQRAtsNVFAMFD
Upstream
Downstream
58 354
Effects on Modified Protein
  • intracellular localization
Effects on Biological Processes:
  • cell motility, altered
  • cytoskeletal reorganization
Kinase, in vitro:
  • AurB (human)
  • DAPK1 (human)
  • DAPK1 (mouse)
  • DAPK3 (human)
  • DLK (human)
  • ILK (human)
  • ROCK1 (human)
  • smMLCK (human)
Putative in vivo kinases:
  • DAPK3 (human)
  • ILK (human)
  • ROCK1 (human)
  • smMLCK (human)
Regulatory protein:
  • ACTG1 (human)
  • AFAP1L1 (human)
  • ARHGAP22 (human)
  • Cas-L (human)
  • DLC1 (human)
  • DOCK3 (human)
  • FAM40B (human)
  • HRas (mouse)
  • ITGB3 (human)
  • MST3 (human)
  • MST4 (human)
  • PLK3 (human)
  • RAC1 (human)
  • RAF1 (human)
  • ROCK1 (human)
  • SG2NA (human)
  • Src (human)
  • STRIP1 (human)
  • WAVE2 (human)
Treatment
  • 5-HT
  • ACh
  • angiotensin_2
  • anti-CD3
  • anti-EPCR
  • APC
  • arachidonic_acid
  • BX795
  • C3_toxin
  • calyculin_A
  • cell_detachment
  • Clostridium_toxin_B
  • compound_C
  • CPA
  • DPDPE
  • EDTA
  • EGF
  • ephrin_A1
  • exoenzyme_C3
  • fibronectin
  • GF109203X
  • HA-1077
  • integrilin
  • isoproterenol
  • LY294002
  • M-1
  • metastatic potential
  • miRNA
  • NaB
  • nocodazole
  • okadaic_acid
  • ONO-3708
  • PD184352
  • phorbol_ester
  • PIK
  • PP2
  • PP3
  • racepinefrine
  • SB203580
  • serum
  • serum_starvation
  • siRNA
  • somatostatin
  • Su11274
  • SU6656
  • thrombin
  • TxA2
  • vanadate
  • Y27632
  • yohimbine
MRLC2 (human) KRPQRAtsNVFAMFD S20-p
MRLC2 (mouse) KRPQRAtsNVFAMFD S20-p
MRLC2 (rat) KRPQRAtsNVFAMFD S20-p
MRLC2 (cow) KRPQRAtsNVFAMFD S20-p
S29-p
VFAMFDQsQIQEFKE
0 14
MRLC2 (human) VFAMFDQsQIQEFKE S29-p
MRLC2 (mouse) VFAMFDQsQIQEFKE S29-p
MRLC2 (rat) VFAMFDQSQIQEFKE S29
MRLC2 (cow) VFAMFDQSQIQEFKE S29
K51-ac
NRDGFIDkEDLHDML
0 2
MRLC2 (human) NRDGFIDkEDLHDML K51-ac
MRLC2 (mouse) NRDGFIDKEDLHDML K51
MRLC2 (rat) NRDGFIDkEDLHDML K51-ac
MRLC2 (cow) NRDGFIDKEDLHDML K51
K51-ub
NRDGFIDkEDLHDML
0 6
MRLC2 (human) NRDGFIDkEDLHDML K51-ub
MRLC2 (mouse) NRDGFIDkEDLHDML K51-ub
MRLC2 (rat) NRDGFIDKEDLHDML K51
MRLC2 (cow) NRDGFIDKEDLHDML K51
T97-p
FGEKLNGtDPEDVIR
0 2
MRLC2 (human) FGEKLNGtDPEDVIR T97-p
MRLC2 (mouse) FGEKLNGTDPEDVIR T97
MRLC2 (rat) FGEKLNGTDPEDVIR T97
MRLC2 (cow) FGEKLNGTDPEDVIR T97
T135-p
TTMGDRFtDEEVDEL
Upstream
1 34
Kinase, in vitro:
  • CK2A1 (human)
MRLC2 (human) TTMGDRFtDEEVDEL T135-p
MRLC2 (mouse) TTMGDRFtDEEVDEL T135-p
MRLC2 (rat) TTMGDRFTDEEVDEL T135
MRLC2 (cow) TTMGDRFTDEEVDEL T135
Y143-p
DEEVDELyREAPIDk
0 3
MRLC2 (human) DEEVDELyREAPIDk Y143-p
MRLC2 (mouse) DEEVDELYREAPIDk Y143
MRLC2 (rat) DEEVDELYREAPIDK Y143
MRLC2 (cow) DEEVDELYREAPIDK Y143
K150-ub
yREAPIDkkGNFNyI
Upstream
0 6
Treatment
  • MG132
MRLC2 (human) yREAPIDkkGNFNyI K150-ub
MRLC2 (mouse) YREAPIDkkGNFNYI K150-ub
MRLC2 (rat) YREAPIDKKGNFNYI K150
MRLC2 (cow) YREAPIDKKGNFNYI K150
K151-ub
REAPIDkkGNFNyIE
Upstream
0 25
Treatment
  • MG132
MRLC2 (human) REAPIDkkGNFNyIE K151-ub
MRLC2 (mouse) REAPIDkkGNFNYIE K151-ub
MRLC2 (rat) REAPIDKKGNFNYIE K151
MRLC2 (cow) REAPIDKKGNFNYIE K151
Y156-p
DkkGNFNyIEFTRIL
0 52
MRLC2 (human) DkkGNFNyIEFTRIL Y156-p
MRLC2 (mouse) DkkGNFNYIEFTRIL Y156
MRLC2 (rat) DKKGNFNYIEFTRIL Y156
MRLC2 (cow) DKKGNFNYIEFTRIL Y156
K164-ub
IEFTRILkHGAkDKD
0 1
MRLC2 (human) IEFTRILkHGAkDKD K164-ub
MRLC2 (mouse) IEFTRILKHGAKDKD K164
MRLC2 (rat) IEFTRILKHGAKDKD K164
MRLC2 (cow) IEFTRILKHGAKDKD K164
K168-ac
RILkHGAkDKDD___
0 1
MRLC2 (human) RILkHGAkDKDD___ K168-ac
MRLC2 (mouse) RILKHGAKDKDD___ K168
MRLC2 (rat) RILKHGAKDKDD___ K168
MRLC2 (cow) RILKHGAKDKDD___ K168